Ipca Laboratories Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3pb8d8jzbnq0cyn77i735yab.pdf

Key Takeaways


Domestic Formulation: The Standout Engine

Harish Kamath: "See, what was happening, any incremental raw material cost, we used to pass on. But unfortunately, the situation was not so in the last 2 financial years because of stocking and other situation. But hopefully, going forward, everything should get normalized."

Unichem Turnaround & Integration

Ajit Kumar Jain: "So I would say that we are confident in whatever we had talked around acquisition time and all. We are confident that all those things will be achieved. And better than that would be achieved, yes."

US Market: The Build-Out Begins

Ajit Kumar Jain: "Overall, let's say, that as far as U.S. is concerned, we have not started so far filing the ANDAs from our plants because it will take -- we had -- nothing we had in the pipeline for U.S. And pipeline is now building. So people are working now in R&D and thereafter, buyback shares will be taken. Stability will take a lot of time, 6 to 7 months time and then data compilation."

Export Formulation: Generics Offset Branded Weakness


Margins: Material Costs Drove the Step-Up

Harish Kamath: "Our aim is to reach ultimately to that level of around 24%, 25% over the next 6, 7 years."

API & Other Businesses


Guidance & Commitments

CommitmentSpecificsTimeline
Standalone revenue growth10.5–11%FY25
Consolidated revenue growth14–14.25%FY25
Standalone EBITDA marginImprove from 19.29% to 20.5–21%FY25
Consolidated EBITDA marginImprove from 16.72% to ~18%FY25
Unichem EBITDAReach ~INR225 cr (from INR100 cr)FY25
US product launches6–7 products from approved portfolioFY25
All 25–26 approved US products in marketCommercialised across ~3 yearsOver 3 years
Margin trajectory100–150 bps improvement per yearNext 2–3 years
Long-term margin target24–25%Next 6–7 years
R&D spend3.25–3.5% of salesFY25
Consolidated capexINR300–350 cr (total ~INR500 cr)FY25

Key Metrics

MetricQ4 FY24
Stand-alone revenue growth~10.5% to 11% guided for FY25
Consolidated revenue growth~14% to 14.25% guided for FY25
Stand-alone EBITDA margin~18.5%, up from 11.29% in Q4 FY23
Consolidated EBITDA margin~14.98%, up from 11.29% in Q4 FY23
Stand-alone EBITDA margin (full year)~19.29%, up from 16.22% in FY23
Consolidated EBITDA margin (full year)~16.72%, up from 15.3% in FY23
Material cost to sales ratio (stand-alone, full year)~32.08%, improved from 35.58% in FY23
Domestic formulation growth (Q4)~13%
Domestic formulation growth (IQVIA, Q4)15%, vs IPM growth of ~6%
Acute segment growth (IQVIA, Q4)~11%, vs market growth of 3%
Chronic segment growth (IQVIA, Q4)~12%, vs market growth of ~10%
Overall market share (IQVIA)2.04%, up from 1.88% in March 2023
Top 6 metros growth (IQVIA)~16%, vs market growth of ~8%
Export formulation growth (Q4)~9%
Generic export growth (full year)~22% to ~INR801 cr
R&D spend (Ipca + Unichem)~INR250 cr, ~3.25% to 3.5% of sales
U.S. product launches expected (FY25)6 to 7 products
Unichem EBITDA (FY24)INR100 cr, up from minus INR45 cr in FY23
Unichem EBITDA guidance (FY25)~INR225 cr
Consolidated capex guidance (FY25)~INR500 cr
U.S. facilities EBITDA drag~INR50 cr to INR60 cr